Aug. 4 at 7:51 PM
$NVAX My guesses, based on observations over many years as a stockholder in this fine company, but it's still a guess, is that ...
1. JJ likes nice surprises, meaning that he aims to present good results but does not upstage himself with overly histrionic messaging (we're not selling sham-wows here), and ...
2. He knows the astonishing potential of our Matrix-M immunostimilant, and that it (again, my guesses) extends far beyond vaccines and into therapeutics such as oncology drugs, HIV-AIDS and other infectious disease treatment, and more.
3 A further guess is that some of the discussions with second-party pharma need to be discrete at the formative, testing phases of communication.
